Zomedica Corp. (ZOM): ANSOFF MATRIX [Dec-2025 Updated]

You're staring at Zomedica Corp.'s current position and need to know exactly where the next dollar of growth is coming from, right? After analyzing their 2025 performance-like the $5.4 million in Q3 TRUFORMA consumable revenue and that solid 16% international sales growth-it's clear they have four distinct paths forward. We've broken down the actionable strategies, from aggressively pushing VETIGEL in the existing U.S. market to seriously considering moving their $0.7 million Development Services segment into human health applications. Honestly, these aren't abstract ideas; they are specific plays based on current product adoption and regulatory wins like the ISO 13485 certification. Dive into the matrix below to see the precise plans for market penetration, development, product expansion, and even diversification that will define Zomedica Corp.'s next phase.

Zomedica Corp. (ZOM) - Ansoff Matrix: Market Penetration

You're looking at how Zomedica Corp. can grow by selling more of its existing products into its current veterinary markets. This is about driving deeper adoption, and the numbers from the third quarter of 2025 show some real traction here.

Increase TRUFORMA assay utilization to boost $5.4 million Q3 consumable revenue.

The focus on driving utilization of the TRUFORMA diagnostic platform is clearly paying off in the consumable revenue stream. For the third quarter of 2025, consumable revenues hit $5.4 million, which is a 14% increase compared to the third quarter of 2024. Year-to-date through Q3 2025, consumable revenue growth stands at 15% year-on-year. This recurring revenue stream is key, representing about 68% of total revenue in the third quarter of 2024, and the growth is directly tied to the accelerating adoption of TRUFORMA and the continued strong sales of PulseVet trodes from both new and existing systems. The Diagnostics segment itself saw a massive 51% year-over-year growth in Q3 2025. That's defintely a strong indicator of assay use.

Here's a quick look at the Q3 2025 financial snapshot to put that consumable number in context:

Offer bundled pricing on PulseVet systems and trode reorders to drive recurring sales.

The Therapeutic Device segment, which includes PulseVet, posted $6.7 million in revenue for Q3 2025, showing a 3% increase year-over-year. While the capital sales of the devices bring in upfront revenue, the strategy here is to lock in the recurring trode reorders. The growth in consumables is explicitly linked to reorders associated with existing systems. This bundling approach helps lower the initial barrier to entry for the PulseVet system while securing a predictable revenue stream from the necessary trode consumables over the life of the device.

Cross-sell VETIGEL hemostatic gel across the existing $2 billion U.S. veterinary market.

The total addressable annual market for Zomedica Corp.'s recurring revenue products is stated to be over $2.5 billion, with the capital sales market over $1 billion. While specific VETIGEL sales figures aren't broken out, the strategy involves pushing this product into the existing installed base, which is part of the broader consumables growth noted above. The goal is to capture a piece of that $2 billion U.S. veterinary market by leveraging the existing customer relationships built through TRUFORMA and PulseVet sales.

Expand the dedicated equine sales force to accelerate PulseVet adoption in current U.S. clinics.

Zomedica Corp. is making targeted investments in next-generation devices and specifically mentioned equine VETGuardian and new TRUFORMA assays. The launch of the equine progesterone assay for the TRUFORMA platform on December 4, 2025, signals a dedicated push into the equine segment, which supports the need for an expanded, specialized sales presence. The company is focused on leveraging its commercial infrastructure, which has already seen international sales grow by 20% year-to-date through Q3 2025.

Run targeted promotions to convert competitive diagnostic platform users.

The 51% growth in the Diagnostics segment in Q3 2025, driven by TRUFORMA adoption, suggests successful efforts to displace older testing methods. The TRUFORMA platform uses Bulk Acoustic Wave (BAW) technology, which offers reference lab performance at the point of care, a strong value proposition against traditional reference lab testing. The expansion of the TRUFORMA menu, including the feline cobalamin & folate assay, provides more reasons for users of competitive platforms to switch to Zomedica Corp.'s solution for faster, in-clinic results.

You need to track the conversion rate from competitive platforms against the growth in new assay utilization. Finance: draft 13-week cash view by Friday.

Zomedica Corp. (ZOM) - Ansoff Matrix: Market Development

Leverage the 16% Q3 2025 international sales growth by securing new EU distributors.

The Diagnostics segment revenue grew by 51% in Q3 2025, while Therapeutic Device segment revenue grew by 3% in the same period, contributing to the overall 16% year-over-year revenue increase to $8.1 million for Q3 2025.

Target major veterinary markets in Asia-Pacific with the PulseVet shock wave system.

The Asia Pacific companion animal health market size was estimated at USD 4.51 billion in 2024. This market is projected to reach USD 11.26 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 10.73% from 2025 to 2033. China held the largest revenue share of 19.10% in the Asia Pacific companion animal health market in 2024. The broader Asia-Pacific veterinary medicine market is expected to reach USD 19.42 billion by 2032 from USD 10.28 billion in 2024, growing at a CAGR of 6.5% from 2025 to 2032.

Expand TRUFORMA platform sales beyond North America, focusing on the UK and Netherlands.

Zomedica Corp. strengthened partnerships with Grovet b.v. in the Netherlands and secured a strategic distribution agreement with Pioneer Veterinary Products Limited in the United Kingdom during Q3 2025. The expanded agreement with Grovet b.v. includes distribution rights for the TRUFORMA diagnostic platform for companion animals [cite: 6 from previous search]. The Diagnostics segment, which includes TRUFORMA, generated $0.7 million in revenue in Q3 2025.

Utilize ISO 13485 certification to streamline regulatory entry into new global markets.

Zomedica Corp. announced it earned ISO 13485:2016 certification on November 6, 2025, for its manufacturing and distribution operations in Plymouth, Minnesota and Roswell, Georgia. This certification is expected to support regulatory filings and enhance the ability to expand globally.

Establish a defintely stronger presence in South American companion animal clinics.

The company's strategy includes expansion in Central and South American regions. A partnership with SIRE Veterinario, S.A. in Costa Rica aims to bring products to approximately 3,000 veterinarians in that country [cite: 5 from previous search, 9].

International Sales and Liquidity Metrics (Q3 2025)

Key Product Adoption Metrics

• Diagnostics segment growth (YoY): 51%.
• Therapeutic Device segment growth (YoY): 3%.
• Consumable sales growth (Q1 2025 YoY): 13% [cite: 6 from previous search].
• Assisi Loop units treated to date (cumulative): more than 50,000 pets [cite: 10 from previous search].
• PulseVet systems in use globally (as of 2021): 1,500 systems [cite: 8 from previous search].

Zomedica Corp. (ZOM) - Ansoff Matrix: Product Development

You're looking at how Zomedica Corp. is building out its product line, which is the core of the Product Development quadrant in the Ansoff Matrix. This is where the company invests its resources to create new offerings for its existing veterinary market. For context, Zomedica Corp. reported total revenue of $8.1 million for the third quarter ended September 30, 2025, with $1.8 million spent on Research and Development during that period.

The immediate focus is on getting Palinveo, the product for feline hyperthyroidism, through regulatory approval and into the market in existing territories. While specific launch figures aren't public yet, this is clearly a priority to build upon the existing Diagnostics segment, which already saw revenue growth of 51% year-over-year in Q3 2025, reaching $0.7 million.

Zomedica Corp. is actively expanding the TRUFORMA diagnostic platform with new assays. They recently added feline testing capability to the cobalamin & folate assay, which delivers results in under 25 minutes. This platform expansion is supported by intellectual property growth, as the company secured four additional U.S. patents to protect its TRUFORMA and TRUVIEW systems.

Integrating advanced technology into existing systems is also key. You should expect the launch of the TRUVIEW AI system within the next few weeks from the November 21, 2025, earnings call, signaling a move toward AI-powered diagnostics.

For the Assisi Loop therapeutic line, the focus is on new form factors to cover diverse pet sizes. The existing line already includes the Assisi LOOP Lounge® for total body treatment, the DentaLOOP™ for oral pain, and the Calmer Canine Anxiety Treatment System®. To date, the tPEMF technology in the Assisi LOOP line has been used to treat over 50,000 pets safely and successfully.

Building on the success of point-of-care diagnostics in companion animals, Zomedica Corp. launched its equine progesterone assay on December 4, 2025, directly targeting reproductive health. This taps into a significant market; the global equine reproduction market was valued at approximately $485 million in 2024. For scale, the North American Thoroughbred foal crop has been around 18,500 live foals recently, and the American Quarter Horse Association registered about 81,213 foals in 2020.

Here's a quick look at the segment performance driving the investment in these product developments:

Specific product development achievements and near-term milestones include:

• Prioritized launch of Palinveo for feline hyperthyroidism in existing markets.
• Expansion of TRUFORMA platform with new assays, including feline cobalamin & folate.
• Secured four new U.S. patents related to TRUFORMA and TRUVIEW IP.
• TRUVIEW AI launch expected 'within the next few weeks' from November 21, 2025.
• Launched the equine progesterone assay on December 4, 2025.
• Assisi Loop technology has treated over 50,000 pets to date.

The total addressable market for recurring revenue products is estimated to be over $2.5 billion, and the capital sales market is over $1 billion. Finance: draft 13-week cash view by Friday.

Zomedica Corp. (ZOM) - Ansoff Matrix: Diversification

You're looking at Zomedica Corp.'s next big leap, moving beyond the established animal health space. This is about taking what you've built-the quality systems and the technology-and applying it elsewhere. Honestly, the groundwork for this is already showing up in the financials.

The Development Services segment is your first tangible step into this new territory. For the third quarter ended September 30, 2025, this segment booked $0.7 million in revenue. That $700,000 came directly from work done on behalf of a company in the human health space. That's not just a side project; it's a proof point that your engineering and production capabilities translate. The goal now is to expand that segment's focus, moving from project-based revenue to more structured human health development contracts.

Your existing infrastructure is the engine for this diversification. You've got certified facilities and proven technology platforms. Here's a quick look at the assets supporting this move:

Securing the ISO 13485:2016 certification across your Plymouth, Minnesota, and Roswell, Georgia, sites is defintely key here. This standard is the international benchmark for medical device quality management systems. It directly supports regulatory filings and customer assurance needed to offer contract manufacturing and R&D services to the human medical device sector. This formal quality infrastructure is what positions Zomedica Corp. to pursue these higher-bar opportunities.

The path forward involves leveraging specific technologies for new markets. You're looking at translating proven radar-based monitoring and advanced material science into human applications. The VETGuardian system, which uses patented Doppler technology for contact-free vital sign monitoring (temperature, pulse, respiration) in animals, has already cleared the CE mark hurdle. This opens the door to developing non-veterinary remote monitoring products for human use, perhaps starting with home care or low-acuity settings. Similarly, the VETIGEL technology, currently a registered trademark, presents an opportunity for licensing discussions related to human surgical or emergency medical applications.

To accelerate this diversification, concrete actions are necessary:

• Expand Development Services revenue beyond the $0.7 million Q3 2025 baseline into dedicated human health contracts.
• Finalize licensing agreements for VETIGEL in human surgical settings.
• Identify and acquire a small human medical device company with existing regulatory clearance.
• Actively market contract manufacturing slots leveraging the ISO 13485 certified facilities.
• Initiate a pilot program for non-veterinary remote monitoring based on VETGuardian technology.

Finance: draft 13-week cash view by Friday.